Santoro et al. compare plasma p-tau217 concentrations in individuals with Down syndrome regression disorder, Down syndrome without regression, and typical neurodevelopment as controls. P-tau217 levels...

The p-tau217 blood marker shows stronger diagnostic performance for most Alzheimer's stages than p-tau181.

People with subjective cognitive decline showed a high burden of modifiable dementia risks, while elevated p-Tau217 was linked to early signs of neurodegeneration, and sharing biomarker results may encourage healthier lifestyle changes. Study: Dementia risk factors and biomarkers in subjective cognitive decline: real world evidence from the monza brain health service. Image credit: pathdoc/Shutterstock.com A recent paper published in the journal Neurological Sciences reported a high prevalence of modifiable risk factors among individuals with subjective cognitive decline (SCD). It also revealed signs of neurodegeneration among SCD individuals with suprathreshold levels of the dementia biomarker phosphorylated Tau217 (p-Tau217). Finally, structured disclosure of biomarker results and risk estimates was well accepted, and about 60% of participants who underwent disclosure reported greater motivation for lifestyle changes. Why subjective cognitive decline matters for dementia prevention Up to 45% of dementia cases could potentially be prevented or delayed by addressing 14 modifiable risk factors identified by the Lancet Commission, putting growing emphasis on prevention among people who may be at increased risk of cognitive decline. One group attracting particular attention is people with subjective cognitive decline (SCD), who notice changes in their cognition even though they continue to perform normally on standard cognitive tests. SCD...

Blood biomarkers are transforming clinical practice for Alzheimer's disease.1 Plasma phosphorylated tau-217 (p-tau217), a highly sensitive and specific marker of Alzheimer's disease pathology,2 has en...

No description available

Background and ObjectivesCentral and general adiposity have been linked to dementia risk, but their relation to blood-based Alzheimer disease (AD) biomarkers is unclear. We examined life course adipos...

El Global Research Summit es un programa formativo anual de Ace Alzheimer Center Barcelona dirigido a profesionales de la neurología, psiquiatría, geriatría,

25 September 2026 (Navroze Bureau)  A blood biomarker known as phosphorylated tau 217 (p-tau217) is emerging as a promising tool for the earlier detection of Alzheimer’s disease, potentially allowing doctors to identify biological changes associated with the disease before significant symptoms or cognitive decline become apparent. Researchers are studying whether p-tau217 could eventually complement or reduce reliance on more invasive and expensive diagnostic approaches such as…

25 September 2026 Punjab Khabarnama Bureau  : A blood biomarker known as phosphorylated tau 217 (p-tau217) is emerging as a promising tool for the earlier detection of Alzheimer’s disease, potentially allowing doctors to identify biological changes associated with the disease before significant symptoms or cognitive decline become apparent. Researchers are studying whether p-tau217 could eventually complement or reduce reliance on more invasive and expensive diagnostic approaches such as…

Background Measurement of different tau species using immunoassays has proven effective for detecting early Alzheimer’s disease (AD) pathology. However, assay performance depends on factors such as th...

A investigación CompAS, iniciada en 2008, identifica a reserva cognitiva, a memoria, a marcha, a atrofia hipocampal e biomarcadores como a p-tau217 entre os factores que permiten detectar an ...

Kan p-tau217 testi Alzheimer biyolojisini kanla tespit ediyor; uzmanlar erken tanı ve dikkatli yorum çağrısı yapıyor.

A ciência contribuiu para dispormos de dois medicamentos com demonstrada eficácia no atraso da doença. Em Portugal, apenas estão disponíveis para prescrição no sistema privado.